Novo Nordisk loses its obesity-drug lead as Lilly gains ground, raising questions over pipeline depth, patent expiry and future growth.
Regulatory watch intensifies as the EU and FDA clear new treatments while India rewires sterile-drug licensing, digital regulation and CDSCO capacity.
This Week in Biosimilars highlights oncology taking the Lead in India as Dr. Reddy’s enters the nivolumab market and competition expands patient access.
Merck joins India’s crowded biomanufacturing push as global life-science suppliers expand local capacity, training infrastructure and customer support.
AstraZeneca’s England approval of Enhertu signals wider access to cancer care, expanding NHS treatment options for eligible breast cancer patients.
Science still finds insufficient evidence to support stem cell therapy as standard care for autism, keeping the treatment within clinical trials.
Today’s pharma deals map the full innovation cycle, spanning oral biologics discovery, vaccine market access, and gene-therapy regulatory approval.
Pharma investment is accelerating across hospitals, biosimilars, manufacturing and healthcare infrastructure, revealing changing industry growth priorities.
Gilead just raised the bar in the long-acting HIV prevention race with expanded licensing for investigational once-yearly lenacapavir.
A new MRI dye could help map tiny lung tumors and hidden metastases, offering earlier detection without radiation.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")